Legal & General Group PLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$1.39 - $2.21 $11,402 - $18,128	-8,203 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$0.94 - $1.89 $2,622 - $5,273	-2,790 Reduced 25.38%	8,203 $10,000
Q3 2020 Nov 13, 2020	SELL	$1.5 - $9.38 $4,032 - $25,213	-2,688 Reduced 19.65%	10,993 $20,000
Q2 2020 Aug 14, 2020	BUY	$4.79 - $8.39 $14,044 - $24,599	2,932 Added 27.28%	13,681 $114,000
Q1 2020 May 14, 2020	SELL	$3.44 - $7.21 $4,062 - $8,515	-1,181 Reduced 9.9%	10,749 $56,000
Q4 2019 Feb 13, 2020	BUY	$4.29 - $5.64 $10,300 - $13,541	2,401 Added 25.2%	11,930 $65,000
Q1 2019 May 15, 2019	BUY	$5.76 - $8.95 $7,603 - $11,813	1,320 Added 16.08%	9,529 $66,000
Q4 2018 Feb 15, 2019	BUY	$5.26 - $7.97 $5,528 - $8,376	1,051 Added 14.68%	8,209 $48,000
Q2 2018 Aug 10, 2018	SELL	$5.05 - $6.8 $7,479 - $10,070	-1,481 Reduced 17.14%	7,158 $36,000
Q1 2018 May 17, 2018	SELL	$5.6 - $9.25 $16,816 - $27,777	-3,003 Reduced 25.79%	8,639 $52,000
Q4 2017 Feb 13, 2018	BUY	$6.6 - $7.78 $76,837 - $90,574	11,642	11,642 $83,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.